Find Ivacaftor manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 873054-44-5, Vx-770, Kalydeco, Ivacaftor (vx-770), N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide, Vx 770
Molecular Formula
C24H28N2O3
Molecular Weight
392.5  g/mol
InChI Key
PURKAOJPTOLRMP-UHFFFAOYSA-N
FDA UNII
1Y740ILL1Z

Ivacaftor
Ivacaftor (also known as Kalydeco or VX-770) is a drug used for the management of Cystic Fibrosis (CF). It is manufactured and distributed by Vertex Pharmaceuticals. It was approved by the Food and Drug Administration on January 31, 2012, and by Health Canada in late 2012. Ivacaftor is administered as a monotherapy and also administered in combination with other drugs for the management of CF. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes. CFTR is active in epithelial cells of organs such as of the lungs, pancreas, liver, digestive system, and reproductive tract. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to complications such as infections, lung damage, pancreatic insufficiency, and malnutrition. Prior to the development of ivacaftor, management of CF primarily involved therapies for the control of infections, nutritional support, clearance of mucus, and management of symptoms rather than improvements in the underlying disease process or lung function (FEV1). Notably, ivacaftor was the first medication approved for the management of the underlying causes of CF (abnormalities in CFTR protein function) rather than control of symptoms.
Ivacaftor is a Cystic Fibrosis Transmembrane Conductance Regulator Potentiator. The mechanism of action of ivacaftor is as a Chloride Channel Activation Potentiator, and Cytochrome P450 2C9 Inhibitor, and P-Glycoprotein Inhibitor, and Cytochrome P450 3A Inhibitor.
1 2D Structure

Ivacaftor

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1H-quinoline-3-carboxamide
2.1.2 InChI
InChI=1S/C24H28N2O3/c1-23(2,3)16-11-17(24(4,5)6)20(27)12-19(16)26-22(29)15-13-25-18-10-8-7-9-14(18)21(15)28/h7-13,27H,1-6H3,(H,25,28)(H,26,29)
2.1.3 InChI Key
PURKAOJPTOLRMP-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)C1=CC(=C(C=C1NC(=O)C2=CNC3=CC=CC=C3C2=O)O)C(C)(C)C
2.2 Other Identifiers
2.2.1 UNII
1Y740ILL1Z
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-

2. Kalydeco

3. N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

4. N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

5. Vx-770

2.3.2 Depositor-Supplied Synonyms

1. 873054-44-5

2. Vx-770

3. Kalydeco

4. Ivacaftor (vx-770)

5. N-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

6. Vx 770

7. N-[2,4-bis(tert-butyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-3-quinolinecarboxamide

8. Chebi:66901

9. N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1h-quinoline-3-carboxamide

10. 1y740ill1z

11. 1413431-05-6

12. 3-quinolinecarboxamide, N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-1,4-dihydro-4-oxo-

13. N-(2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

14. Vx770

15. 3-quinolinecarboxamide, N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxo-

16. Kalydeco (tn)

17. Ivacaftor [usan]

18. Ivacaftor [usan:inn]

19. Ivacaftorum

20. Unii-1y740ill1z

21. Ivacaftor D18

22. Vx7

23. Ivacaftor [inn]

24. Ivacaftor [mi]

25. Ivacaftor (usan/inn)

26. Vx-770 - Ivacaftor

27. Ivacaftor [vandf]

28. Ivacaftor [who-dd]

29. Mls006011119

30. Schembl351373

31. Gtpl4342

32. Ivacaftor [orange Book]

33. Vx-770, Ivacaftor, Kalydeco

34. Chembl2010601

35. Dtxsid00236281

36. Ex-a441

37. Orkambi Component Ivacaftor

38. Symkevi Component Ivacaftor

39. Bcpp000199

40. Hms3654e10

41. Hms3744k05

42. Trikafta Component Ivacaftor

43. Bcp19794

44. Bdbm50032693

45. Mfcd17171361

46. S1144

47. Zinc52509463

48. Ivacaftor Component Of Orkambi

49. Akos015994762

50. Akos032950001

51. Ivacaftor Component Of Trikafta

52. Bcp9000799

53. Ccg-268562

54. Cs-0497

55. Db08820

56. Ex-7211

57. Le-0002

58. Sb16815

59. Ncgc00242480-01

60. Ncgc00242480-03

61. Ac-28324

62. Hy-13017

63. Smr004702900

64. Ft-0696681

65. Sw219620-1

66. Ec-000.2478

67. A25626

68. D09916

69. Ab01565806_02

70. Q6095693

71. Ctp-656; Ctp-656; Ctp-656; D9-ivacaftor;vx-561

72. Cystic Fibrosis Transmembrane Conductance Regulator Potentiator

73. N-(5-hydroxy-2,4-ditert-butyl-phenyl)-4-oxo-1h-quinoline-3-carboxamide

74. N-(2,4-ditert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide

75. N-(5-hydroxy-2,4-bis(2-methyl-2-propanyl)phenyl]-4-oxo-1,4-dihydro-3-quinolinecarboxamide

76. N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide

77. 1134822-00-6

78. Ivacaftor;n-(2,4-di-tert-butyl-5-hydroxyphenyl)-4-oxo-1,4-dihydroquinoline-3-carboxamide;ivacaftor

2.4 Create Date
2007-07-23
3 Chemical and Physical Properties
Molecular Weight 392.5 g/mol
Molecular Formula C24H28N2O3
XLogP35.6
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count4
Rotatable Bond Count4
Exact Mass392.20999276 g/mol
Monoisotopic Mass392.20999276 g/mol
Topological Polar Surface Area78.4 Ų
Heavy Atom Count29
Formal Charge0
Complexity671
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Information
1 of 2  
Drug NameKalydeco
PubMed HealthIvacaftor (By mouth)
Drug ClassesRespiratory Agent
Drug LabelThe active ingredient in KALYDECO tablets is ivacaftor, which has the following chemical name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. Its molecular formula is C24H28N2O3 and its molecular weight is 392.49. Iva...
Active IngredientIvacaftor
Dosage FormTablet
RouteOral
Strength150mg
Market StatusPrescription
CompanyVertex Pharms

2 of 2  
Drug NameKalydeco
PubMed HealthIvacaftor (By mouth)
Drug ClassesRespiratory Agent
Drug LabelThe active ingredient in KALYDECO tablets is ivacaftor, which has the following chemical name: N-(2,4-di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide. Its molecular formula is C24H28N2O3 and its molecular weight is 392.49. Iva...
Active IngredientIvacaftor
Dosage FormTablet
RouteOral
Strength150mg
Market StatusPrescription
CompanyVertex Pharms

4.2 Drug Indication

When used as monotherapy as the product Kalydeco, ivacaftor is indicated for the management of CF in patients age 2 years and older who have a mutation in the CFTR gene that is responsive to ivacaftor potentiation. Ivacaftor received expanded approval in May 2017 for the following 33 CFTR mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349D. When used in combination with the drug [lumacaftor] as the product Orkambi, ivacaftor is indicated for the management of CF patients age 6 years and older who are shown to be homozygous for the F508del mutation in the CFTR gene. When used in combination with [tezacaftor] in the product Symdeko, it is used to manage CF in patients 12 years and older who have at least one mutation in the CFTR gene or patients aged 12 or older who are shown to be homozygous for the F508del mutation. When used in combination with tezacaftor and [elexacaftor] in the product Trikafta, it is indicated for the treatment of cystic fibrosis in patients 12 years of age and older who have at least one _F508del_ mutation in the CFTR gene.


FDA Label


Kalydeco tablets are indicated:

- As monotherapy for the treatment of adults, adolescents, and children aged 6 years and older and weighing 25 kg or more with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4. 4 and 5. 1).

- In a combination regimen with tezacaftor/ivacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who are homozygous for the F508del mutation or who are heterozygous for the F508del mutation and have one of the following mutations in the CFTR gene: P67L, R117C, L206W, R352Q, A455E, D579G, 711+3AG, S945L, S977F, R1070W, D1152H, 2789+5GA, 3272 26AG, and 3849+10kbCT.

- In a combination regimen with ivacaftor/tezacaftor/elexacaftor tablets for the treatment of adults, adolescents, and children aged 6 years and older with cystic fibrosis (CF) who have at least one F508del mutation in the CFTR gene (see section 5. 1).

Kalydeco granules are indicated for the treatment of infants aged at least 4 months, toddlers and children weighing 5 kg to less than 25 kg with cystic fibrosis (CF) who have an R117H CFTR mutation or one of the following gating (class III) mutations in the CFTR gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R (see sections 4. 4 and 5. 1).


5 Pharmacology and Biochemistry
5.1 Pharmacology

The use of Ivacaftor has been shown to both improve CF symptoms and modulate underlying disease pathology. This is achieved by potentiating the channel opening probability (or gating) of CFTR protein in patients with impaired gating mechanisms. This is in contrast to [DB09280], another CF medication, that functions by preventing misfolding of the CFTR protein and thereby results in increased processing and trafficking of mature protein to the cell surface. Results from clinical trials indicated that treatment with ivacaftor results in improved lung function, reduced chance of experiencing a pulmonary exacerbation, reduced sweat chloride, increased weight gain, and improvements in CF symptoms and quality of life. When combined with tezacaftor, significant improvements in lung function have been observed in clinical studies. Ivacaftor was not found to increase the QTc interval in a clinically significant manner. Although ivacaftor given alone has not shown any significant improvements in patients with the delta-F508 mutation, it has shown significant improvements (>10% increase in FEV1 from baseline) in lung function for the following mutations: E56K, P67L, R74W, D110E, D110H, R117C, R117H, G178R, E193K, L206W, R347H, R352Q, A455E, S549N, S549R, G551D, G551S, D579G, S945L, S977F, F1052V, K1060T, A1067T, G1069R, R1070Q, R1070W, F1074L, D1152H, G1244E, S1251N, S1255P, D1270N, and G1349. This list was expanded by the FDA in May 2017 from 10 to 33 to accommodate more rare mutations. It is important to note that this drug may cause an increase in liver transaminases (ALT, AST). Ensure to assess liver transaminases before the initiation of treatment, every 3 months during the first year of administration, followed by every year thereafter.


5.2 MeSH Pharmacological Classification

Chloride Channel Agonists

A class of drugs that stimulate chloride ion influx through cell membrane channels. (See all compounds classified as Chloride Channel Agonists.)


5.3 FDA Pharmacological Classification
5.3.1 Active Moiety
IVACAFTOR
5.3.2 FDA UNII
1Y740ILL1Z
5.3.3 Pharmacological Classes
Cystic Fibrosis Transmembrane Conductance Regulator Potentiator [EPC]; Cytochrome P450 2C9 Inhibitors [MoA]; Cytochrome P450 3A Inhibitors [MoA]; P-Glycoprotein Inhibitors [MoA]; Chloride Channel Activation Potentiators [MoA]
5.4 ATC Code

R07AX02


R07AX30

S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355


R - Respiratory system

R07 - Other respiratory system products

R07A - Other respiratory system products

R07AX - Other respiratory system products

R07AX02 - Ivacaftor


5.5 Absorption, Distribution and Excretion

Absorption

Ivacaftor is well absorbed in the gastrointestinal tract. Following administration of ivacaftor with fat-containing foods, peak plasma concentrations were reached at 4 hours (Tmax) with a maximum concentration (Cmax) of 768 ng/mL and AUC of 10600 ng * hr/mL. It is recommended that ivacaftor is taken with fat-containing foods as they increase absorption by approximately 2.5- to 4-fold.


Route of Elimination

After oral administration, ivacaftor is mainly eliminated in the feces after metabolic conversion and this elimination represents 87.8% of the dose. From the total eliminated dose, the metabolites M1 and M6 account for the majority of the eliminated dose, being 22% for M1 and 43% for M6. Ivacaftor shows negligible urinary excretion as the unchanged drug.


Volume of Distribution

After oral administration of 150 mg every 12 hours for 7 days to healthy volunteers in a fed state, the mean (SD) for apparent volume of distribution was 353 (122) L.


Clearance

The CL/F (SD) for the 150 mg dose was 17.3 (8.4) L/hr in healthy subjects.


5.6 Metabolism/Metabolites

Ivacaftor is extensively metabolized in humans. In vitro and clinical studies indicate that ivacaftor is primarily metabolized by CYP3A. From this metabolism, the major formed metabolites are M1 and M6. M1 is considered pharmacologically active even though it just presents approximately one-sixth the effect of the parent compound ivacaftor. On the other hand, M6 is not considered pharmacologically active as it represents less than one-fiftieth of the effect of the parent compound.


5.7 Biological Half-Life

In a clinical study, the apparent terminal half-life was approximately 12 hours following a single dose of ivacaftor. One source mentions the half-life ranges from 12 to 14 hours.


5.8 Mechanism of Action

A wide variety of CFTR mutations correlate to the Cystic Fibrosis phenotype and are associated with differing levels of disease severity. The most common mutation, affecting approximately 70% of patients with CF worldwide, is known as F508del-CFTR or delta-F508 (F508), in which a deletion in the amino acid phenylalanine at position 508 results in impaired production of the CFTR protein, thereby causing a significant reduction in the amount of ion transporter present on cell membranes. Ivacaftor as monotherapy has failed to show a benefit for patients with delta-F508 mutations, most likely due to an insufficient amount of protein available at the cell membrane for interaction and potentiation by the drug. The next most common mutation, G551D, affecting 4-5% of CF patients worldwide is characterized as a missense mutation, whereby there is sufficient amount of protein at the cell surface, but opening and closing mechanisms of the channel are altered. Ivacaftor is indicated for the management of CF in patients with this second type of mutation, as it binds to and potentiates the channel opening ability of CFTR proteins on the cell membrane. Ivacaftor exerts its effect by acting as a potentiator of the CFTR protein, an ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Alterations in the CFTR gene result in altered production, misfolding, or function of the protein and consequently abnormal fluid and ion transport across cell membranes. Ivacaftor improves CF symptoms and underlying disease pathology by potentiating the channel open probability (or gating) of CFTR protein in patients with impaired CFTR gating mechanisms. The overall level of ivacaftor-mediated CFTR chloride transport is dependent on the amount of CFTR protein at the cell surface and how responsive a particular mutant CFTR protein is to ivacaftor potentiation.


API SUPPLIERS

read-more
read-more

01

LGM Pharma

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothLGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

Flag U.S.A
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
LGM Pharma CB

02

Metrochem API Private Limited

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMetrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
Metrochem

03

HRV Global Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothHRV Global Life Sciences - Market Expansion Leader in Pharmaceuticals.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
HRV Global Life Sciences

04

Medichem S.A

Spain

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMedichem is a vertically integrated pharmaceutical company specializing in the development & manufacturing of APIs & FDFs.

Flag Spain
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WC NDC arrow-down KDMF VMF Others AUDIT
Medichem

05

Glenmark Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

Glenmark Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WCarrow-down NDC arrow-down KDMF VMF Others AUDIT
blank

06

Vindhya Organics

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

Vindhya Organics

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

07

Vindhya Organics

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

Vindhya Organics

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

08

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

Sun Pharmaceutical Industries Limi...

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

09

AR Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

AR Life Sciences

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

10

Lupin Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

BioFlorida Conference
Not Confirmed
arrow

Lupin Ltd

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
BioFlorida Conference
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Pharmtech & Ingredients
Not Confirmed

01

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2017-07-18

Pay. Date : 2017-06-28

DMF Number : 31849

Submission : 2017-06-30

Status : Active

Type : II

blank

02

Pharmtech & Ingredients
Not Confirmed

03

Pharmtech & Ingredients
Not Confirmed

03

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-10-12

Pay. Date : 2021-08-18

DMF Number : 36209

Submission : 2021-08-19

Status : Active

Type : II

blank

04

Pharmtech & Ingredients
Not Confirmed

04

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2021-08-13

Pay. Date : 2021-07-07

DMF Number : 36094

Submission : 2021-07-07

Status : Active

Type : II

blank

05

Pharmtech & Ingredients
Not Confirmed

05

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-05-19

Pay. Date : 2015-03-10

DMF Number : 28867

Submission : 2015-03-10

Status : Active

Type : II

blank

06

Pharmtech & Ingredients
Not Confirmed

06

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-08-20

Pay. Date : 2020-07-02

DMF Number : 32610

Submission : 2019-03-29

Status : Active

Type : II

blank

07

Pharmtech & Ingredients
Not Confirmed

07

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2023-10-17

Pay. Date : 2023-08-29

DMF Number : 29398

Submission : 2015-05-30

Status : Active

Type : II

blank

08

Scinopharm Taiwan Ltd

Taiwan

USDMF

arrow
Pharmtech & Ingredients
Not Confirmed

08

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 35447

Submission : 2020-12-28

Status : Active

Type : II

blank

09

Pharmtech & Ingredients
Not Confirmed

09

Pharmtech & Ingredients
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2019-09-10

Pay. Date : 2019-07-25

DMF Number : 33783

Submission : 2019-07-26

Status : Active

Type : II

blank

10

Pharmtech & Ingredients
Not Confirmed
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

Fi Europe 2024
Not Confirmed
arrow
arrow
Fi Europe 2024
Not Confirmed

Ivacaftor IH

Date of Issue : 2022-06-17

Valid Till : 2025-07-02

Written Confirmation Number : WC-0082

Address of the Firm : API Division Kharakhadi, Plot No. 842-843, Kharakhadi, Padra Vadodara-391 450, G...

blank

02

Fi Europe 2024
Not Confirmed
arrow
arrow
Fi Europe 2024
Not Confirmed

Ivacaftor IH

Date of Issue : 2022-06-07

Valid Till : 2025-06-25

Written Confirmation Number : WC-0057n

Address of the Firm : Plot No. 3109, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"IVACAFTOR","year":"2021","qtr":"Q1","strtotime":1614105000,"product":"IVACAFTOR - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TUTEUR S.A.C.I.F.I.A.","customerCountry":"ARGENTINA","quantity":"12.00","actualQuantity":"12","unit":"KGS","unitRateFc":"10582.5","totalValueFC":"125669.8","currency":"USD","unitRateINR":762467.08333333337,"date":"24-Feb-2021","totalValueINR":"9149605","totalValueInUsd":"125669.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"8885393","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q3","strtotime":1626028200,"product":"IVACAFTOR - BULK DRUG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"MICROSULES ARGENTINA S.A","customerCountry":"ARGENTINA","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"16000","totalValueFC":"3153.2","currency":"USD","unitRateINR":1175000,"date":"12-Jul-2021","totalValueINR":"235000","totalValueInUsd":"3153.2","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"3058756","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2021","qtr":"Q4","strtotime":1636569000,"product":"IVACAFTOR - BULK DRUG *DATA LOGGER ALONG","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ATHENS, GA","customer":"GENEPHARM S.A","customerCountry":"GREECE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"12000","totalValueFC":"966.8","currency":"USD","unitRateINR":720000,"date":"11-Nov-2021","totalValueINR":"72000","totalValueInUsd":"966.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"5924418","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR IAL ESTATE, MOHOL BAZARPETH, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q1","strtotime":1647801000,"product":"IVACAFTOR","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TUTEUR S.A.C.I.F.I.A","customerCountry":"ARGENTINA","quantity":"6.00","actualQuantity":"6","unit":"KGS","unitRateFc":"10670","totalValueFC":"63159.7","currency":"USD","unitRateINR":802333.33333333337,"date":"21-Mar-2022","totalValueINR":"4814000","totalValueInUsd":"63159.7","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"9069382","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"GENEPHARMA S.A,","customerCountry":"GREECE","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"15000","totalValueFC":"1365.2","currency":"USD","unitRateINR":1030000,"date":"05-Apr-2022","totalValueINR":"103000","totalValueInUsd":"1365.2","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"9491601","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1649097000,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"MADRID","customer":"LICONSA S.A.","customerCountry":"SPAIN","quantity":"0.10","actualQuantity":"0.1","unit":"KGS","unitRateFc":"15000","totalValueFC":"1365.2","currency":"USD","unitRateINR":1030000,"date":"05-Apr-2022","totalValueINR":"103000","totalValueInUsd":"1365.2","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"9491505","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1653589800,"product":"IVACAFTOR","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"REYKJAVIK","customer":"TO THE ORDER..","customerCountry":"ICELAND","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"8000","totalValueFC":"3972.3","currency":"USD","unitRateINR":614000,"date":"27-May-2022","totalValueINR":"307000","totalValueInUsd":"3972.3","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"1691772","productDescription":"API","marketType":"REGULATED MARKET","country":"ICELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1655749800,"product":"IVACAFTOR","address":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth","city":"Solapur","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"TO THE ORDER","customerCountry":"GREECE","quantity":"0.30","actualQuantity":"0.3","unit":"KGS","unitRateFc":"12000","totalValueFC":"3448","currency":"USD","unitRateINR":896666.66666666674,"date":"21-Jun-2022","totalValueINR":"269000","totalValueInUsd":"3448","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"2280230","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"Plot 170-172, Chandramouli Industrial Estate, Mohol Bazarpeth, Solapur","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1657477800,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"KINGFISHER","customer":"CORIPHARMA EHF,","customerCountry":"ICELAND","quantity":"0.25","actualQuantity":"0.25","unit":"KGS","unitRateFc":"12000","totalValueFC":"2703.8","currency":"USD","unitRateINR":860000,"date":"11-Jul-2022","totalValueINR":"215000","totalValueInUsd":"2703.8","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"2727623","productDescription":"API","marketType":"REGULATED MARKET","country":"ICELAND","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1665945000,"product":"IVACAFTOR","address":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL","city":"AHMEDABAD,GUJARAT","supplier":"APRAMEYA PHARMACHEM PVT LTD","supplierCountry":"INDIA","foreign_port":"DUBAI","customer":"KING PRIME GLOBAL PROCUREMENT TRADI","customerCountry":"UNITED ARAB EMIRATES","quantity":"0.85","actualQuantity":"0.85","unit":"KGS","unitRateFc":"10340","totalValueFC":"8482.8","currency":"EUR","unitRateINR":821176.4705882353,"date":"17-Oct-2022","totalValueINR":"698000","totalValueInUsd":"8482.8","indian_port":"BOMBAY AIR","hs_no":"29339990","bill_no":"4882424","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"UNITED ARAB EMIRATES","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"A-2,419, CELEBRATION CITY CENTER,, GALA GYM ROAD,SOUTH BOPAL,BOPAL, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q4","strtotime":1670956200,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"REMEDICA LTD","customerCountry":"CYPRUS","quantity":"0.05","actualQuantity":"0.05","unit":"KGS","unitRateFc":"11000","totalValueFC":"449","currency":"USD","unitRateINR":740000,"date":"14-Dec-2022","totalValueINR":"37000","totalValueInUsd":"449","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"6146514","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1674153000,"product":"IVACAFTOR","address":"Kalpataru Inspire, 3rd floor, off Western Express Highway Santacruz E","city":"Mumbai","supplier":"LUPIN LTD","supplierCountry":"INDIA","foreign_port":"BARCELONA","customer":"MEDICHEM S.A","customerCountry":"SPAIN","quantity":"5.00","actualQuantity":"5","unit":"KGS","unitRateFc":"12000","totalValueFC":"58965.7","currency":"USD","unitRateINR":964200,"date":"20-Jan-2023","totalValueINR":"4821000","totalValueInUsd":"58965.7","indian_port":"BANGALORE AIR","hs_no":"29420090","bill_no":"7137902","productDescription":"API","marketType":"REGULATED MARKET","country":"SPAIN","selfForZScoreResived":"Pharma Grade","supplierPort":"BANGALORE AIR","supplierAddress":"Kalpataru Inspire, 3rd floor, off Western Express Highway Santacruz E, Mumbai","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q1","strtotime":1679337000,"product":"IVACAFTOR","address":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA","city":"VISAKHAPATNAM,ANDHRA PRADESH","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"CANADA","quantity":"21.00","actualQuantity":"21","unit":"KGS","unitRateFc":"10000","totalValueFC":"208521.9","currency":"USD","unitRateINR":816714.28571428568,"date":"21-Mar-2023","totalValueINR":"17151000","totalValueInUsd":"208521.9","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"8641664","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOTNO21JAWAHARLAL NEHRU PHARMACIT Y,PARAWADA, VISAKHAPATNAM,ANDHRA PRADESH","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1683225000,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"AQUILA HARMACEUTICAL MEDICINAL CHEM","customerCountry":"CYPRUS","quantity":"3.93","actualQuantity":"3.93","unit":"KGS","unitRateFc":"11000","totalValueFC":"42328.9","currency":"USD","unitRateINR":886259.54198473284,"date":"05-May-2023","totalValueINR":"3483000","totalValueInUsd":"42328.9","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1684780200,"product":"MSN ACTIVE PHARMACEUTICAL PRODUCT AS PERATTACHED INVOICE NO 1900235139 IVACAFTOR","address":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD","city":"HYDERABAD","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"VILNIUS","customer":"TO THE ORDER","customerCountry":"LITHUANIA","quantity":"0.01","actualQuantity":"0.01","unit":"KGS","unitRateFc":"12500","totalValueFC":"24.3","currency":"USD","unitRateINR":200000,"date":"23-May-2023","totalValueINR":"2000","totalValueInUsd":"24.3","indian_port":"HYDERABAD AIR","hs_no":"29333990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"LITHUANIA","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"MSN HOUSE, PLOT NO. C-24,INDUSTRIAL HYDERABAD, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q2","strtotime":1686076200,"product":"IVACAFTOR","address":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET","city":"HYDERABAD","supplier":"AUROBINDO PHARMA LIMITED","supplierCountry":"INDIA","foreign_port":"LARNACA","customer":"REMEDICA LTD","customerCountry":"CYPRUS","quantity":"4.00","actualQuantity":"4","unit":"KGS","unitRateFc":"11000","totalValueFC":"43627.3","currency":"USD","unitRateINR":896499.92249999999,"date":"07-Jun-2023","totalValueINR":"3585999.69","totalValueInUsd":"43627.3","indian_port":"HYDERABAD AIR","hs_no":"29339990","bill_no":"0","productDescription":"API","marketType":"REGULATED MARKET","country":"CYPRUS","selfForZScoreResived":"Pharma Grade","supplierPort":"HYDERABAD AIR","supplierAddress":"PLOT NO.2, MAITRIVIHAR BEHIND MAITRIVANAM, AMEERPET, HYDERABAD","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1698431400,"product":"IVACAFTOR","address":"MSN HOUSE, PLOT NO. C-24,","city":"HYDERABAD. AP","supplier":"MSN LABORATORIES","supplierCountry":"INDIA","foreign_port":"ALGIERS","customer":"TO THE ORDER OF","customerCountry":"ALGERIA","quantity":"9.00","actualQuantity":"9","unit":"KGS","unitRateFc":"25000","totalValueFC":"222794.1","currency":"USD","unitRateINR":2060333.3333333333,"date":"28-Oct-2023","totalValueINR":"18543000","totalValueInUsd":"222794.1","indian_port":"Hyderabad Air","hs_no":"29333990","bill_no":"4951946","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ALGERIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"MSN HOUSE, PLOT NO. C-24,, HYDERABAD. AP","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q4","strtotime":1700677800,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS - (API) IVACAFTOR","address":"ALEMBIC ROAD","city":"GUJARAT","supplier":"ALEMBIC PHARMACEUTICALS LIMITED","supplierCountry":"INDIA","foreign_port":"YELGRAD (BEOGRAD)","customer":"TO THE ORDER OF","customerCountry":"SERBIA","quantity":"1.50","actualQuantity":"1.5","unit":"KGS","unitRateFc":"9500","totalValueFC":"13954.5","currency":"USD","unitRateINR":774666.66666666663,"date":"23-Nov-2023","totalValueINR":"1162000","totalValueInUsd":"13954.5","indian_port":"Ahmedabad Air","hs_no":"29339990","bill_no":"5526611","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"SERBIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ALEMBIC ROAD, GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"IVACAFTOR","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"SANOVEL ILAC SAN.VE TIC.A.S.,","customerCountry":"TURKEY","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"15000","totalValueFC":"2162.8","currency":"USD","unitRateINR":1198386.6666666667,"date":"17-Jan-2024","totalValueINR":"179758","totalValueInUsd":"2162.8","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6813733","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1705429800,"product":"IVACAFTOR","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"SANOVEL ILAC SAN.VE TIC.A.S.,","customerCountry":"TURKEY","quantity":"0.15","actualQuantity":"0.15","unit":"KGS","unitRateFc":"15000","totalValueFC":"2162.8","currency":"USD","unitRateINR":1198386.6666666667,"date":"17-Jan-2024","totalValueINR":"179758","totalValueInUsd":"2162.8","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"6813778","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1709231400,"product":"IVACAFTOR","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"CANADA","quantity":"52.00","actualQuantity":"52","unit":"KGS","unitRateFc":"6000","totalValueFC":"307037.2","currency":"USD","unitRateINR":490289.96192307689,"date":"01-Mar-2024","totalValueINR":"25495078.02","totalValueInUsd":"307037.2","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"7988652","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q1","strtotime":1710354600,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32418004996 DT. 06.03.2024: IVACAFTOR","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"BUENOS AIRES","customer":"TO THE ORDER..","customerCountry":"ARGENTINA","quantity":"6.50","actualQuantity":"6.5","unit":"KGS","unitRateFc":"12000","totalValueFC":"76806.8","currency":"USD","unitRateINR":981186.6046153846,"date":"14-Mar-2024","totalValueINR":"6377712.93","totalValueInUsd":"76806.8","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"8314000","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"ARGENTINA","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1712341800,"product":"IVACAFTOR","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ATHENS","customer":"PHARMAPTHA S .A","customerCountry":"GREECE","quantity":"36.00","actualQuantity":"36","unit":"KGS","unitRateFc":"6750","totalValueFC":"239788","currency":"USD","unitRateINR":556223.5,"date":"06-Apr-2024","totalValueINR":"20024046","totalValueInUsd":"239788","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"8946922","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1714415400,"product":"SD15101 IVACAFTOR (GGL-D151) BATCHNO: 802307767","address":"5\/502, GARDEN ESTATE,","city":"THANE, MAHARASHTRA.","supplier":"AMTEC HEALTHCARE PVT LTD","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"TRANSFARMA DIS TICARET ANONIM SIR,,","customerCountry":"TURKEY","quantity":"1.00","actualQuantity":"1","unit":"KGS","unitRateFc":"386656","totalValueFC":"4566.7","currency":"INR","unitRateINR":381351.53999999998,"date":"30-Apr-2024","totalValueINR":"381351.54","totalValueInUsd":"4566.7","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9525591","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"5\/502, GARDEN ESTATE,, THANE, MAHARASHTRA.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715193000,"product":"ACTIVE PHARMACEUTICALS INGREDIENTS (API)EXPORT INVOICE NUMBER : F32518000378 DT. 30.04.2024 IVACAFTOR","address":"PLOT 170-172, CHANDRAMOULI,INDUSTR","city":"SOLAPUR,MAHARASHTRA","supplier":"GLENMARK PHARMACEUTICALS","supplierCountry":"INDIA","foreign_port":"ATH","customer":"TO THE ORDER","customerCountry":"GREECE","quantity":"0.20","actualQuantity":"0.2","unit":"KGS","unitRateFc":"11178","totalValueFC":"2223.4","currency":"USD","unitRateINR":926653.99999999988,"date":"09-May-2024","totalValueINR":"185330.8","totalValueInUsd":"2223.4","indian_port":"Bombay Air","hs_no":"29339990","bill_no":"9739402","productDescription":"API","marketType":"REGULATED MARKET","country":"GREECE","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"PLOT 170-172, CHANDRAMOULI,INDUSTR, SOLAPUR,MAHARASHTRA","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1716489000,"product":"IVACAFTOR","address":"2ND FLOOR, SERENE CHAMBERS,","city":"","supplier":"LAURUS LABS","supplierCountry":"INDIA","foreign_port":"TORONTO","customer":"TEVA PHARMACEUTICAL INDUSTRIES","customerCountry":"CANADA","quantity":"78.00","actualQuantity":"78","unit":"KGS","unitRateFc":"6000","totalValueFC":"462255.6","currency":"USD","unitRateINR":493986.34525641025,"date":"24-May-2024","totalValueINR":"38530934.93","totalValueInUsd":"462255.6","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"1126491","productDescription":"API","marketType":"REGULATED MARKET","country":"CANADA","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"2ND FLOOR, SERENE CHAMBERS,, ","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1729017000,"product":"IVACAFTOR","address":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower","city":"Hyderabad","supplier":"APITORIA PHARMA PRIVATE LIMITED","supplierCountry":"INDIA","foreign_port":"ISTANBUL","customer":"SANOVEL ILAC SAN.VE TIC.A.S.,","customerCountry":"TURKEY","quantity":"0.50","actualQuantity":"0.5","unit":"KGS","unitRateFc":"15000","totalValueFC":"7271.4","currency":"USD","unitRateINR":1221984,"date":"16-Oct-2024","totalValueINR":"610992","totalValueInUsd":"7271.4","indian_port":"Hyderabad Air","hs_no":"29339990","bill_no":"4867663","productDescription":"API","marketType":"LESS REGULATED MARKET","country":"TURKEY","selfForZScoreResived":"Pharma Grade","supplierPort":"Hyderabad Air","supplierAddress":"Floor No.22, Plot No.1, Survey No.83\/1, Galaxy Tower, Hyderabad","customerAddress":""}]
24-Feb-2021
16-Oct-2024
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

Kalydeco (ivacaftor) is an oral, CFTR potentiator, small molecule drug candidate. It is now approved for the treatment of cystic fibrosis in patients aged 1 month and older.


Lead Product(s): Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Kalydeco

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2024

blank

01

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kalydeco (ivacaftor) is an oral, CFTR potentiator, small molecule drug candidate. It is now approved for the treatment of cystic fibrosis in patients aged 1 month and older.

Brand Name : Kalydeco

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2024

blank

Details:

Kalydeco (ivacaftor) is an oral, CFTR potentiator, small molecule drug candidate. It is being evaluated for the treatment of cystic fibrosis in patients aged 1 month and older.


Lead Product(s): Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Kalydeco

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 23, 2024

blank

02

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kalydeco (ivacaftor) is an oral, CFTR potentiator, small molecule drug candidate. It is being evaluated for the treatment of cystic fibrosis in patients aged 1 month and older.

Brand Name : Kalydeco

Molecule Type : Small molecule

Upfront Cash : Not Applicable

February 23, 2024

blank

Details:

Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 24, 2023

blank

03

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 24, 2023

blank

Details:

Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.


Lead Product(s): Ivacaftor,Tezacaftor,Elexacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 23, 2023

blank

04

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of cystic fibrosis in patients aged 2 years & above.

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

November 23, 2023

blank

Details:

Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of children With cystic fibrosis ages 2 through 5.


Lead Product(s): Elexacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Kaftrio

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 15, 2023

blank

05

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kaftrio (ivacaftor/tezacaftor/elexacaftor) is an oral medicine designed to binding to different sites on the CFTR protein, which is investigated for the treatment of children With cystic fibrosis ages 2 through 5.

Brand Name : Kaftrio

Molecule Type : Small molecule

Upfront Cash : Not Applicable

September 15, 2023

blank

Details:

Orkambi is a combination of lumacaftor which improves the conformational stability of F508del-CFTR and ivacaftor, a CFTR potentiator. It is being used for cystic fibrosis in patients aged 1 year and older who have two copies of the F508del mutation in CFTR gene.


Lead Product(s): Lumacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Orkambi

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 05, 2023

blank

06

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Orkambi is a combination of lumacaftor which improves the conformational stability of F508del-CFTR and ivacaftor, a CFTR potentiator. It is being used for cystic fibrosis in patients aged 1 year and older who have two copies of the F508del mutation in CF...

Brand Name : Orkambi

Molecule Type : Small molecule

Upfront Cash : Not Applicable

July 05, 2023

blank

Details:

ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.


Lead Product(s): Exaluren Sulfate,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: ELX-02

Study Phase: Phase IIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 14, 2023

blank

07

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : ELX-02 exaluren) is a small molecule drug candidate designed to restore production of full-length functional proteins. It is being developed for the treatment of CF patients with nonsense mutations.

Brand Name : ELX-02

Molecule Type : Small molecule

Upfront Cash : Not Applicable

June 14, 2023

blank

Details:

Kalydeco (ivacaftor) is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. it has received USFDA approval to treat eligible infants with CF ages 1 month and older.


Lead Product(s): Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Kalydeco

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 03, 2023

blank

08

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Kalydeco (ivacaftor) is a potentiator of the CFTR protein. The CFTR protein is a chloride channel present at the surface of epithelial cells in multiple organs. it has received USFDA approval to treat eligible infants with CF ages 1 month and older.

Brand Name : Kalydeco

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 03, 2023

blank

Details:

Orkambi is a combination of lumacaftor which improves the conformational stability of F508del-CFTR and ivacaftor is a CFTR potentiator. It is being used for cystic fibrosis in patients aged 1 year and older who have two copies of the F508del mutation in CFTR gene.


Lead Product(s): Lumacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Orkambi

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 27, 2023

blank

09

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Orkambi is a combination of lumacaftor which improves the conformational stability of F508del-CFTR and ivacaftor is a CFTR potentiator. It is being used for cystic fibrosis in patients aged 1 year and older who have two copies of the F508del mutation in ...

Brand Name : Orkambi

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 27, 2023

blank

Details:

Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein at the cell surface.


Lead Product(s): Elexacaftor,Tezacaftor,Ivacaftor

Therapeutic Area: Genetic Disease Brand Name: Trikafta

Study Phase: ApprovedProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 26, 2023

blank

10

Fi Europe 2024
Not Confirmed
Fi Europe 2024
Not Confirmed

Details : Trikafta is a combination drug where elexacaftor and tezacaftor bind to different sites of CFTR and additionally facilitates the cellular processing and trafficking of mutated CFTR. Ivacaftor potentiates the channel open probability of the CFTR protein a...

Brand Name : Trikafta

Molecule Type : Small molecule

Upfront Cash : Not Applicable

April 26, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

INTERMEDIATES SUPPLIERS

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothMalladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.

CAS Number : 13593-94-7

End Use API : Ivacaftor

About The Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufa...

Malladi

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSoujanya Life Sciences makes API & intermediates for various therapeutic categories including Antidiabetic, Anti-Hypertensive, etc.

CAS Number : 13721-01-2

End Use API : Ivacaftor

About The Company : Soujanya Life Sciences is a new division of the Soujanya Group, a 40-year-old organization with a strong presence in 50 countries and expertise in pigments and ...

Soujanya

03

Pharmtech & Ingredients
Not Confirmed
arrow
Pharmtech & Ingredients
Not Confirmed
arrow

CAS Number : 873055-57-3

End Use API : Ivacaftor

About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

blank

04

Pharmtech & Ingredients
Not Confirmed
arrow
Pharmtech & Ingredients
Not Confirmed
arrow

CAS Number : 13721-01-2

End Use API : Ivacaftor

About The Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and ch...

blank

05

Pharmtech & Ingredients
Not Confirmed
arrow
Pharmtech & Ingredients
Not Confirmed
arrow

CAS Number : 873055-58-4

End Use API : Ivacaftor

About The Company : VIDGAS aims to provide our pharmaceutical, Bio pharma, Agrochemical, Food and Fine chemical customers with the highest quality SFC and HPLC purification and iso...

blank

06

Pharmtech & Ingredients
Not Confirmed
arrow
Pharmtech & Ingredients
Not Confirmed
arrow

CAS Number : 13721-01-2

End Use API : Ivacaftor

About The Company : VIDGAS aims to provide our pharmaceutical, Bio pharma, Agrochemical, Food and Fine chemical customers with the highest quality SFC and HPLC purification and iso...

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Fillers, Diluents & Binders

read-more
read-more

Direct Compression

read-more
read-more

Coating Systems & Additives

read-more
read-more

Granulation

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Co-Processed Excipients

read-more
read-more

Taste Masking

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

API Stability Enhancers

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Vegetarian Capsules

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty